Education
About Us
Working with TipRanks
Follow Us
Ezekowitz Alan Insider Profile
4 Followers
Ezekowitz Alan, Director at Fulcrum Therapeutics, holds ― shares in Fulcrum Therapeutics (Ticker: FULC), holds ― shares in Organon (Ticker: OGN), holds 117.42K shares in Septerna, Inc. (Ticker: SEPN). Most recently, Ezekowitz Alan ― shares of Fulcrum Therapeutics on ― for an estimated value of ―.
Profitable Transactions
2 out of 2 Profitable Transactions
Average Return
+105.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Ezekowitz Alan holds in companies
Most Profitable Insider Trade
The most profitable trade made by Ezekowitz Alan
Ezekowitz Alan's Trading History
Fulcrum Therapeutics
―
Director
―
―
Organon
―
Director
―
―
Septerna, Inc.
Mar 10, 2025
Director
Informative Buy
92.17K
$1.59M
List of latest transactions for each holding click on a transaction to see Ezekowitz Alan's performance on stock
You May Also Like
Ezekowitz Alan insider profile FAQ
What is the percentage of profitable transactions made by Ezekowitz Alan?
The percentage of profitable transactions made by Ezekowitz Alan is 100%.
What is the average return per transaction made by Ezekowitz Alan?
The average return per transaction made by Ezekowitz Alan is 105.50%.
What stocks does Ezekowitz Alan hold?
Ezekowitz Alan holds: FULC, OGN, SEPN stocks.
What was Ezekowitz Alan’s latest transaction?
Ezekowitz Alan latest transaction was an Uninformative Buy of ―.
What was Ezekowitz Alan's most profitable transaction?
Ezekowitz Alan’s most profitable transaction was an Informative Buy of SEPN stock on March 10, 2025. The return on the trade was 113.70%.
What is Ezekowitz Alan's role in Fulcrum Therapeutics?
Ezekowitz Alan's role in Fulcrum Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.